The DOI matches its Crossref record; 173 of the 174 references it cites were found in a registry or an index; 34 of the 178 sources its claims cite were checked for support.
The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials
Open accessAbstract
Behavioral variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder characterized by diverse and prominent changes in behavior and personality. One of the greatest challenges in bvFTD is to capture, measure and predict its disease progression, due to clinical, pathological and genetic heterogeneity. Availability of reliable outcome measures is pivotal for future clinical trials and disease monitoring. Detection of change should be objective, clinically meaningful and easily assessed, preferably associated with a biological process. The purpose of this scoping review is to examine the status of longitudinal studies in bvFTD, evaluate current assessment tools and propose potential progression markers. A systematic literature search (in PubMed and Embase.com ) was performed. Literature on disease trajectories and longitudinal validity of frequently-used measures was organized in five domains: global functioning, behavior, (social) cognition, neuroimaging and fluid biomarkers. Evaluating current longitudinal data, we propose an adaptive battery, combining a set of sensitive clinical, neuroimaging and fluid markers, adjusted for genetic and sporadic variants, for adequate detection of disease progression in bvFTD.
Overview
CoChat Summary
TL;DR
This scoping review of 149 studies concludes that no single measure adequately captures behavioral variant frontotemporal dementia (bvFTD) progression and recommends a multimodal, bvFTD-specific battery adjusted for genetic versus sporadic variants. It identifies FTD-specific clinical scales, social cognition questionnaires, structural/functional neuroimaging, and neurofilament light (NfL) as the most evidence-supported candidate progression markers.
Key findings
- The search generated 4,931 articles (2,245 PubMed, 2,686 Embase), 2,842 after deduplication, and 149 included articles; evidence was organized into global functioning, behavior, (social) cognition, neuroimaging, and fluid biomarkers.
- For global functioning and behavior, FTLD-CDR is useful for coarse staging but has low sensitivity; FTD-FRS captures multi-domain deterioration over 1–5 years; FBI and CBI-R were more consistently sensitive to progression in sporadic and genetic bvFTD over 1–4 years than the NPI. DAS and SRI are promising but have limited or lacking follow-up.
- For cognition and social cognition, ACE-R is a more valid cognitive progression screener with marked decline over 1–5 years, whereas MMSE decline is modest or lacking and unrelated to frontotemporal imaging changes; composite scores increase sensitivity. Social cognition tools such as EK-60, IRI, and RSMS are promising, but longitudinal evidence is limited or inconsistent.
- For neuroimaging and fluid biomarkers, MRI grey matter atrophy and DTI white matter changes detect progression, with DTI possibly preceding grey matter atrophy; FDG-PET and ASL show metabolic/perfusion changes. NfL in CSF or serum increased over 9–12 months in genetic and sporadic bvFTD and predicted prodromal-to-symptomatic conversion in genetic bvFTD; most other fluid markers still need longitudinal validation. The paper notes that 70% of bvFTD cases are non-genetic, yet leading progression studies, especially neuroimaging, were predominantly in genetic cohorts.
Methods
- Scoping review conducted according to PRISMA; systematic search in PubMed and Embase.com from inception to September 5, 2022, without date or language restrictions, using terms for “behavioral,” “frontotemporal dementia,” and “longitudinal studies”; duplicates removed with Endnote X20.4 using the Amsterdam Efficient Deduplication method and Bramer-method.
- Two reviewers screened titles/abstracts and full texts. Inclusion required a bvFTD population and either multiple follow-up measurements or relevant cross-sectional associations with disease progression/severity; exclusions were case reports, animal studies, reviews, and studies focused on topics other than disease progression.
- Methodological quality was weighed by diagnostic accuracy (probable or definite bvFTD by international criteria), sample size, follow-up time, and appropriateness of outcome measures; findings were narratively synthesized across five prespecified domains, and meta-analysis was not performed.
Limitations
- Stated: heterogeneous cohorts (genetically undefined versus mutation-specific patients), variable follow-up time, mixed longitudinal and cross-sectional designs, and use of staging instruments less sensitive for bvFTD seriously complicated comparative weighing of results; meta-analysis was therefore not possible.
- Stated: most large and leading progression studies, particularly neuroimaging studies, were predominantly performed in genetic bvFTD cohorts; sporadic cases are typically diagnosed later, are less well defined, and often rely on clinical diagnosis rather than underlying pathology, so current recommendations rest on fewer validation studies in sporadic bvFTD.
- Evident: the search ended September 5, 2022, so later literature is not captured; the paper also states that social cognition tools require further longitudinal, preferably cross-cultural validation and improved psychometrics to overcome floor effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
20 Valid · 6 Not valid · 92 Not checked · 26 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The majority of longitudinal studies (including a clinico-pathological study) supported a crescendo-decrescendo trajectory of behavior in bvFTD, in which progressive and diverse behavioral disturbances were followed by dominating apathy (Chow et al., 2012; O’Connor et al., 2016; Borges et al., 2019; Cosseddu et al., 2019).”
§ The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials > Results > Behavior
What the sources say
- Supportedcites Chow et al., 2012 source
The Abstract describes progressively severe behavioral disturbance followed by increasing apathy in bvFTD and says the results support a crescendo-decrescendo trajectory. The Introduction describes the later stage as one in which apathy dominates. This paper supports the trajectory attributed to it; the sentence’s reference to a majority of studies and a clinico-pathological study concerns the cited group, not necessarily this paper individually. (LLM, conf=0.88)
- Partly supportedcites O’Connor et al., 2016 sourceExperimental — accuracy not yet measured
The Results and Discussion (page numbers unavailable) report that disinhibition and stereotypical behavior declined over time in bvFTD while apathy increased, supporting the later-phase pattern. The paper does not establish an earlier crescendo of diverse behavioral disturbances or show that apathy came to dominate all other symptoms; eating changes also increased. Its own longitudinal findings cannot establish what a majority of studies found. (LLM, conf=0.84)
- Disputedcites Borges et al., 2019 sourceExperimental — accuracy not yet measured
The longitudinal Results (page unavailable) report that in bvFTD with FTLD neuropathology, apathy alone remained at the same frequency from baseline to last visit, while the combination of apathy and disinhibition decreased. This does not show progressive behavioral disturbances followed by apathy becoming dominant; it reports a contrary pattern for apathy alone. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Longitudinal studies, with 9 to 12 months follow-up, concluded levels of CSF or serum NfL increased over time, in both genetic and sporadic bvFTD (Ljubenkov et al., 2018; Gendron et al., 2022).”
§ The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials > Results > Fluid biomarkers
What the sources say
- Disputedcites Ljubenkov et al., 2018 sourceExperimental — accuracy not yet measured
The Results section, “CSF NfL levels over time,” reports no statistically significant increase in CSF NfL in the FTD cohort or the bvFTD subgroup. The Discussion says the study did not detect a consistent increase over time; one bvFTD participant had an increase over nine months, but that does not support the claimed conclusion for both genetic and sporadic bvFTD. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites Gendron et al., 2022 sourceExperimental — accuracy not yet measured
The Results section, “Plasma NfL increases throughout presymptomatic and symptomatic disease phases” (page unavailable), reports faster NfL increases in genetic bvFTD mutation carriers. But this study measured plasma, not CSF or serum, NfL; its rate analysis used measurements at least one year apart and excluded bvFTD patients without a mutation because too few had follow-up measurements. It therefore does not establish the claimed 9–12-month increase in both genetic and sporadic bvFTD. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The Neuropsychiatric Inventory (NPI), developed to evaluate psychopathology in AD (Cummings et al., 1994), generally showed increased scores during follow-up in bvFTD (Linds et al., 2015; Da Silva et al., 2021).”
§ The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials > Results > Behavior
What the sources say
- Partly supportedcites Linds et al., 2015 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports an initial rise in total NPI scores in an earlier bvFTD dataset, but says those scores subsequently declined. In this study, the Results report that NPI-apathy increased after lower initial scores but decreased after higher initial scores; neither passage supports a general increase in NPI scores during follow-up. (LLM, conf=0.84)
- Not checked yetcites Da Silva et al., 2021
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Similar to the FBI, the Cambridge Behavioral Inventory-Revised (CBI-R) assesses frequency of FTD-related symptoms (Nagahama et al., 2006; Wear et al., 2008).”
§ The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials > Results > Behavior
What the sources say
- Not checked yetcites Nagahama et al., 2006 source
- Supportedcites Wear et al., 2008 source
The paper describes the CBI-R as a shorter version of the CBI that retains items assessing behavioural symptoms. It states that the CBI rates how frequently behaviours occur on a 0–4 scale, and the Results section reports that the CBI-R captures behavioural profiles in bv-FTD. The inventory also covers other neurodegenerative disorders; the claim does not say it is exclusive to FTD. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Such clinical, pathological and genetic heterogeneity complicates the pursuit for a reliable biomarker of disease progression in bvFTD (Meeter et al., 2017).”
§ The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials > Introduction
What the sources say
- Supportedcites Meeter et al., 2017 source
The Introduction says sensitive biomarkers are crucial because FTD is heterogeneous and describes poor correspondence between clinical presentation and underlying pathology in bvFTD. It also identifies staging biomarkers as a means of assessing disease severity; the Conclusions describe the continuing search for biomarkers to monitor progression. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
82 more claims · 11 with their cited sources checked
Create a free account to see all 144 claims and to verify the 140 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 17
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, biomarkers relevant for bvFTD, such as neurofilament light chain in CSF and synaptic proteins such as Synaptophysin and GAP4398, 99, 100 were not available.”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [99]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials > Discussion
“Regarding fluid biomarkers, NfL was most researched and most valid, clearly showing significant decline over time.”
§ The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials > Results > Fluid biomarkers
“Longitudinal studies, with 9 to 12 months follow-up, concluded levels of CSF or serum NfL increased over time, in both genetic and sporadic bvFTD (Ljubenkov et al., 2018; Gendron et al., 2022).”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
Measuring individual differences in empathy: Evidence for a multidimensional approach.
Davis, M. H. (1983) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.44.1.113 · Cited by 10,272
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Research works printed but not linked: 2
- Aw, 2002, Facial expressions of emotion: stimuli and tests (FEEST)
- Malpetti, 2022, Synaptic loss in behavioural variant frontotemporal dementia revealed by [
Cited by
Hazelton, J. L., Della Bella, G., Barttfeld, P., Dottori, M., Gonzalez-Gomez, R., Migeot, J., Moguilner, S., Legaz, A., Hernandez, H., Prado, P., et al. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105614 · Cited by 14
Chatzidimitriou, E., Ntritsos, G., Lagoudaki, R., Poptsi, E., Tsardoulias, E., Symeonidis, A. L., Tsolaki, M., Konstantinopoulou, E., Papadopoulou, K., Charalambous, P., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15100466 · Cited by 16
Quantitative assessment of brain atrophy in bvFTD: Implications for diagnostic conversion
Beydoun, C., Quang, H., Matis, S., Hazelton, J. L., Carrick, J., Fumagalli, G., Piguet, O., & Landín-Romero, R. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70307 · Cited by 1
Diagnosis and management of frontotemporal dementia: a narrative review
Cenacchi, V., Lombardo, T., Palacino, F., Cattaruzza, T., Manganotti, P., & Benussi, A. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2687481 · Cited by 2
Advances in diffusion MRI in frontotemporal dementia
Ferraro, P. M., & Spinelli, E. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-23812-3.00009-6
Metadata
- Authors
- Fieldhouse, J. L. P., van Paassen, D. N., van Engelen, M.-P. E., De Boer, S. C. M., Hartog, W. L., Braak, S., Schoonmade, L. J., Schouws, S. N. T. M., Krudop, W. A., Oudega, M. L., Mutsaerts, H. J. M. M., Teunissen, C. E., Vijverberg, E. G. B., & Pijnenburg, Y. A. L.
- Affiliations
- Amsterdam Neuroscience (NL)
- Vrije Universiteit Amsterdam (NL)
- GGZ inGeest (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Fieldhouse, Jay L. P.
- van Paassen, Dirk N.
- ORCID
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2024-05-09
- Volume
- 16
- Pages
- 1382593-1382593
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC11112081
- OpenAlex
- W4396775414
- Cited by
- 8
- References
- 174
- Citations by year
- 2026: 6 · 2025: 2
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Stichting Dioraphte
- Alzheimer Nederland
- Amsterdam Neuroscience
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
- Keywords
- behavioral variant frontotemporal dementia, disease progression, outcome measures, clinical trial design, longitudinal study, disease trajectories, global functioning, behavior, social cognition, neuroimaging biomarkers, fluid biomarkers, genetic heterogeneity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials. https://app.cochat.ai/papers/10.3389/fnagi.2024.1382593
- The paper
- Fieldhouse, J. L. P., van Paassen, D. N., van Engelen, M.-P. E., De Boer, S. C. M., Hartog, W. L., Braak, S., Schoonmade, L. J., Schouws, S. N. T. M., Krudop, W. A., Oudega, M. L., Mutsaerts, H. J. M. M., Teunissen, C. E., Vijverberg, E. G. B., & Pijnenburg, Y. A. L. (2024). The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2024.1382593
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.